Abstract 367P
Background
MET amplification is a rare genetic mutation which can be treated with small-molecule inhibitor-crizotinib. Based on the detection of next-generation sequencing, the molecular characteristics and the efficacy of crizotinib among different subsets of MET amplification in lung cancer patients is poorly understood.
Methods
From January 2018 to April 2019, patients with MET amplification detected by next-generation sequencing were retrospectively collected and the efficacy of crizotinib among different subsets of patients were analyzed.
Results
In our study, 4.16% (112/2694) patients were found to have MET amplification and only 19 patients treated with monotherapy crizotinib. Among the 112 MET amplification patients, primary (with or without other mutation) MET amplification accounted for 3.27% (82/2507) and 16.04% (30/187) re-biopsy patients were found to have acquired MET amplification after the failed treatment of EGFR-TKI. The frequency of MET amplification combined with EGFR 21L858R was slightly higher than that of MET amplification combined with EGFR 19 del (primary or acquired). Primary MET amplification can occur simultaneously with EGFR 20ins or ALK rearrangement. In survival analysis, the median PFS of 10 patients with copy number greater than 4 (CN > 4) seems longer than the nine patients with copy number less than or equal to 4 (CN ≤ 4) (4.7 months vs 2.7 months) and the two curves were separate, but failed to get a statistical significance (p = 0.085). No significant difference has been discovered between the median PFS of primary (4.04 months; 95%CI: 0.33-7.74 months) and acquired (2.99 months; 95% CI: 2.51-3.47 months; P = 0.382) MET amplification.
Conclusions
4.16% lung cancer patients were found to have MET amplification based on the detection of NGS. MET amplification patients treated with crizotinib with copy number greater than 4 (CN > 4) seem have longer PFS. No obvious survival difference has been discovered between primary and acquired MET amplification.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract